Freeform Search

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: L23 Not l13

Display: 20 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Side by Side ○ Image

Search | Clear | Interrupt

Search History

DATE: Saturday, August 18, 2007 Purge Queries | Printable Copy | Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L24	L23 Not l13	152	L24
L23	L22 NOT L8	152	L23
L22	L21 and @ad<20031104	168	L22
L21	L20 and (inert near5 (core or matrix or bead$2 or tablet$2 or pellet$2))	299	L21
L20	L19 and ((opioid near5 (agonist or antagonist)) or (naltrexone or oxycodone or Percocet or dihydrone or dinarkon or eucodal or theocodin or oxiconum or oxycodeinon or oxycontin or antaxone or celupan or "en-1639A" or nalorex or nemexin or reVia or trexan))	2380	L20
L19	(bead$2 or tablet$2 or pellet$3) near8 ($5coat$4 or film or $4layer$4)	144582	L19
L18	L17 or ($4layer$4 near5 core)	279642	L18
L17	(bead$2 or tablet$2 or pellet$3) near8 (coat$4 or film or layer$4)	146900	L17
	DB=PGPB,USPT; PLUR=YES; OP=OR		
L16	L15 NOT L8	0	L16
L15	L14 NOT L13	6	L15
L14	(j near David) near Haddox	6	L14
L13	L12 NOT L8	2	L13
L12	L11 and (opioid near (agonist or antagonist))	24	L12

L11	L10 and layer	28	L11
L10	L9 and (core or bead)	31	L10
L9	Curtis near Wright	65	L9
L8	((Benjamin near Oshlack and (core or bead) and layer) and (opioid near (agonist or antagonist)))	26	L8
L7	((Benjamin near Oshlack and (core or bead)) and layer)	73	L7
L6	((Benjamin near Oshlack) and (core or bead))	90	L6
L5	((Benjamin near Oshlack) and (core or bead))	90	L5
L4	(Benjamin near Oshlach)	0	L4
L3	(((2770569 or 3332950 or 3493657 or 3676557 or 3773955 or 3879555 or 3965256 or 3966940 or 4176186 or 4237140 or 4366310 or 4401672 or 4443428 or 4451470 or 4457933 or 4464378 or 4573995 or 4582835 or 4587118 or 4608376 or 4661492 or 4719215 or 4730048 or 4760069 or 4769372 or 4785000 or 4803208 or 4806341 or 4806543 or 4806558 or 4828826 or 4834965 or 4834984 or 4834985 or 4844907 or 4844909 or 4844910 or 4861598 or 4861781 or 4867985 or 4873076 or 4882335 or 4889860 or 4935428 or 4940587 or 4970075 or 4987136 or 4990341 or 5071646 or 5075341 or 5086058 or 5091189 or 5096715 or 5102887 or 5149538 or 5215758 or 5225440 or 5226331 or 5236714 or 5256669 or 5266331 or 5273760 or 5286493 or 5316759 or 5317022 or 5321012 or 5324351 or 5336691 or 5352680 or 5352683 or 5356467 or 5356900 or 5376662 or 5411745 or 5426112 or 5457208 or 5460826 or 5472712 or 5472943 or 5478577 or 5486362 or 5500227 or 5502058 or 5508042 or 5508043 or 5512578 or 5514680 or 5534492 or 5549912 or 5552422 or 5556838 or 5574052 or 5578725 or 5580876 or 5591452 or 5601845 or 5616601 or 5622722 or 5624932 or 5633259 or 5639476 or 5656295 or 5670172 or 5672360 or 5681585 or 5763452 or 5767125 or 5780479 or 5811126 or 5834477 or 5843480 or 5849240 or 5858017 or 5860950 or 5866164 or 5869097 or 5879705 or 5880132 or 5891471 or 5908848 or 5942241 or 5958452 or 5958459 or 5965161 or 5965163 or 5968547 or 5968551 or 5972954 or 5998434 or 6004970 or 6024982 or 6068855 or 6077532 or 6077533 or 6103258 or 6103261 or 6120806 or 6143322 or 6143328 or 6162467 or 6210714 or 6228863 or 6254887 or 6261599 or 6277384 or 6294195 or 6306438 or 6326027 or 6335033 or 6375957 or 6387404 or 6399096 or 6475494 or 6579536 or 6608075 or 6627635 or 6696066 or 6696088 or 6716449 or 7144587).PN. and naltrexone) and oxycodone)	20	L3
L2	(((2770569 or 3332950 or 3493657 or 3676557 or 3773955 or 3879555 or 3965256 or 3966940 or 4176186 or 4237140 or 4366310 or 4401672 or 4443428 or 4451470 or 4457933 or 4464378 or 4573995 or 4582835 or 4587118 or 4608376 or 4661492 or 4719215 or 4730048 or 4760069 or 4769372 or 4785000 or 4803208 or 4806341 or 4806543 or 4806558 or 4828826 or 4834965 or 4834984 or 4834985 or 4844907 or 4844909 or 4844910 or 4861598 or 4861781 or 4867985 or 4873076 or 4882335 or 4889860 or 4935428 or 4940587 or 4970075 or 4987136 or 4990341 or 5071646 or 5075341 or 5086058 or 5091189 or 5096715 or 5102887 or 5149538 or 5215758 or 5225440 or 5226331 or 5236714 or 5256669 or 5266331 or 5273760 or 5286493 or 5316759 or 5317022 or 5321012 or 5324351 or 5336691 or 5352680 or 5352683 or 5356467 or 5356900 or 5376662 or 5411745 or 5426112 or 5457208 or 5460826 or 5472712 or 5472943 or 5478577 or 5486362 or 5500227 or 5502058 or 5508042 or 5508043 or 5512578 or 5514680 or 5534492 or 5549912 or 5552422 or 5556838 or 5574052 or 5578725 or 5580876 or 5591452 or 5601845 or 5616601 or 5622722 or 5624932 or 5633259 or 5639476 or 5656295 or 5670172 or 5672360 or 5681585 or 5763452 or 5767125 or 5780479 or 5811126 or 5834477 or 5843480 or 5849240 or 5858017 or 5860950 or 5866164 or 5869097 or 5879705 or 5880132 or 5891471 or 5908848 or 5942241 or 5958452 or 5958459 or 5965161 or 5965163 or 5968547 or	53	L2

	5968551 or 5972954 or 5998434 or 6004970 or 6024982 or 6068855 or 6077532 or 6077533 or 6103258 or 6103261 or 6120806 or 6143322 or 6143328 or 6162467 or 6210714 or 6228863 or 6254887 or 6261599 or 6277384 or 6294195 or 6306438 or 6326027 or 6335033 or 6375957 or 6387404 or 6399096 or 6475494 or 6579536 or 6608075 or 6627635 or 6696066 or 6696088 or 6716449 or 7144587).PN.) and naltrexone)		
L1	((2770569 or 3332950 or 3493657 or 3676557 or 3773955 or 3879555 or 3965256 or 3966940 or 4176186 or 4237140 or 4366310 or 4401672 or 4443428 or 4451470 or 4457933 or 4464378 or 4573995 or 4582835 or 4587118 or 4608376 or 4661492 or 4719215 or 4730048 or 4760069 or 4769372 or 4785000 or 4803208 or 4806341 or 4806543 or 4806558 or 4828826 or 4834965 or 4834984 or 4834985 or 4844907 or 4844909 or 4844910 or 4861598 or 4861781 or 4867985 or 4873076 or 4882335 or 4889860 or 4935428 or 4940587 or 4970075 or 4987136 or 4990341 or 5071646 or 5075341 or 5086058 or 5091189 or 5096715 or 5102887 or 5149538 or 5215758 or 5225440 or 5226331 or 5236714 or 5256669 or 5266331 or 5273760 or 5286493 or 5316759 or 5317022 or 5321012 or 5324351 or 5336691 or 5352680 or 5352683 or 5356467 or 5356900 or 5376662 or 5411745 or 5426112 or 5457208 or 5460826 or 5472712 or 5472943 or 5478577 or 5486362 or 5500227 or 5502058 or 5508042 or 5508043 or 5512578 or 5514680 or 5534492 or 5549912 or 5552422 or 5556838 or 5574052 or 5578725 or 5580876 or 5591452 or 5601845 or 5616601 or 5622722 or 5624932 or 5633259 or 5639476 or 5656295 or 5670172 or 5672360 or 5681585 or 5763452 or 5767125 or 5780479 or 5811126 or 5834477 or 5843480 or 5849240 or 5858017 or 5860950 or 5866164 or 5869097 or 5879705 or 5880132 or 5891471 or 5908848 or 5942241 or 5958452 or 5958459 or 5965161 or 5965163 or 5968547 or 5968551 or 5972954 or 5998434 or 6004970 or 6024982 or 6068855 or 6077532 or 6077533 or 6103258 or 6103261 or 6120806 or 6143322 or 6143328 or 6162467 or 6210714 or 6228863 or 6254887 or 6261599 or 6277384 or 6294195 or 6306438 or 6326027 or 6335033 or 6375957 or 6387404 or 6399096 or 6475494 or 6579536 or 6608075 or 6627635 or 6696066 or 6696088 or 6716449 or 7144587).PN.)	160	L1

END OF SEARCH HISTORY

```
     (FILE 'HOME' ENTERED AT 21:39:11 ON 18 AUG 2007)

     FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 21:39:35 ON 18 AUG 2007
L1       130672 S (BEAD? OR TABLET? OR PELLET?) (8A) (OVERCOAT? OR COAT? OR FIL
L2          136 S L1 (S) (((OPIOID OR OPIATE) (5A) (AGONIST OR ANTAGONIST)) OR
L3           38 S L2 NOT PD>20031104
L4           38 DUP REM L3 (0 DUPLICATES REMOVED)
L5           38 FOCUS L4 1-
L6           21 S L2 (S) ((HYDROPHOBIC OR FAT? OR HYDROCARBON) (5A) (COAT? OR O
L7           21 DUP REM L6 (0 DUPLICATES REMOVED)
L8           21 FOCUS L7 1-

=> d que L1
L1       130672 SEA (BEAD? OR TABLET? OR PELLET?) (8A) (OVERCOAT? OR COAT? OR
                FILM? OR LAYER?)


=> d que L2
L1       130672 SEA (BEAD? OR TABLET? OR PELLET?) (8A) (OVERCOAT? OR COAT? OR
                FILM? OR LAYER?)
L2          136 SEA L1 (S) (((OPIOID OR OPIATE) (5A) (AGONIST OR ANTAGONIST))
                OR NALTREXONE OR OXYCODONE OR PERCOCET OR DIHYDRONE OR
                DINARKON OR EUCODAL OR THEOCODIN OR OXICONUM OR OXYCODEINON OR
                OXYCONTIN OR ANTAXONE OR CELUPAN OR NALOREX OR NEMEXIN OR
                REVIA OR TREXAN)


=> d que L6
L1       130672 SEA (BEAD? OR TABLET? OR PELLET?) (8A) (OVERCOAT? OR COAT? OR
                FILM? OR LAYER?)
L2          136 SEA L1 (S) (((OPIOID OR OPIATE) (5A) (AGONIST OR ANTAGONIST))
                OR NALTREXONE OR OXYCODONE OR PERCOCET OR DIHYDRONE OR
                DINARKON OR EUCODAL OR THEOCODIN OR OXICONUM OR OXYCODEINON OR
                OXYCONTIN OR ANTAXONE OR CELUPAN OR NALOREX OR NEMEXIN OR
                REVIA OR TREXAN)
L6           21 SEA L2 (S) ((HYDROPHOBIC OR FAT? OR HYDROCARBON) (5A) (COAT?
                OR OVERCOAT? OR FILM? OR LAYER? OR BILAYER? OR (MULTI(3A)
                LAYER?)))
```

L8 ANSWER 1 OF 21 USPATFULL on STN
TI Pharmaceutical products
AB Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.

L8 ANSWER 2 OF 21 USPATFULL on STN
TI Controlled-release compositions containing opioid agonist and antagonist
AB Controlled-release dosage forms containing an opioid agonist; an opioid antagonist; and a controlled release material release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of said opioid antagonist effective to attenuate a side effect of said opioid agonist. The dosage form provides analgesia for at least about 8 hours when administered to human patients. In other embodiments, the dose of antagonist released during the dosing interval enhances the analgesic potency of the opioid agonist.

L8 ANSWER 3 OF 21 USPATFULL on STN
TI Controlled-release compositions containing opioid agonist and antagonist
AB Controlled-release dosage forms containing an opioid agonist; an opioid antagonist; and a controlled release material release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of said opioid antagonist effective to attenuate a side effect of said opioid agonist. The dosage form provides analgesia for at least about 8 hours when administered to human patients. In other embodiments, the dose of antagonist released during the dosing interval enhances the analgesic potency of the opioid agonist.

L8 ANSWER 4 OF 21 USPATFULL on STN
TI Sustained-release gel coated compositions
AB Disclosed in certain embodiments is a coating comprising a pharmaceutically acceptable mixture of gelatin and hydrophobic polymer.

L8 ANSWER 5 OF 21 USPATFULL on STN
TI Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
AB Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.

L8 ANSWER 6 OF 21 USPATFULL on STN
TI Sequestered antagonist formulations
AB Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.

L8 ANSWER 7 OF 21 USPATFULL on STN
TI Tamper-resistant oral opioid agonist formulations
AB Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed

and are not isolated from each other in two distinct layers.

L8 ANSWER 8 OF 21 USPATFULL on STN
TI Tamper-resistant oral opioid agonist formulations
AB Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.

L8 ANSWER 9 OF 21 USPATFULL on STN
TI Tamper-resistant oral opioid agonist formulations
AB Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.

L8 ANSWER 10 OF 21 USPATFULL on STN
TI Sequestered antagonist formulations
AB Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.

L8 ANSWER 11 OF 21 USPATFULL on STN
TI Tamper-resistant oral opioid agonist formulations
AB Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.

L8 ANSWER 12 OF 21 USPATFULL on STN
TI Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
AB Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to impart a bitter taste to an abuser upon administration of the dosage form after tampering.

L8 ANSWER 13 OF 21 USPATFULL on STN
TI Opioid agonist formulations with releasable and sequestered antagonist
AB Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in

releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.

L8 ANSWER 14 OF 21 USPATFULL on STN
TI Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
AB Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.

L8 ANSWER 15 OF 21 USPATFULL on STN
TI Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent
AB Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.

L8 ANSWER 16 OF 21 USPATFULL on STN
TI Pharmaceutical combinations of hydrocodone and naltrexone
AB Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof.

L8 ANSWER 17 OF 21 USPATFULL on STN
TI Methods of administering opioid antagonists and compositions thereof
AB Disclosed in certain embodiments is a method of treating pain in a patient comprising orally administering an opioid antagonist in an effective amount to provide analgesia in a patient in need thereof.

L8 ANSWER 18 OF 21 USPATFULL on STN
TI Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same
AB The present invention relates to co-extruded pharmaceutical compositions and dosage forms comprising an adverse agent, such as an opioid antagonist, which can be sequestered. The pharmaceutical compositions and dosage forms diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to a process for the preparation of such pharmaceutical compositions and dosage forms comprising co-extrusion of a core comprising an adverse agent and a sheath.

L8 ANSWER 19 OF 21 USPATFULL on STN
TI Prolamin-based sustained-release compositions and delayed-onset compositions
AB In one embodiment, the invention relates to sustained-release compositions comprising one or more prolamins, one or more gelling agents, and one or more active agents. Such compositions are particularly useful for controlled delivery of high solubility and/or high dosage active agents. In another embodiment, the present invention relates to delayed-onset compositions comprising a dry coating comprising one or more prolamins and one or more gelling agents.

L8 ANSWER 20 OF 21 USPATFULL on STN
TI Pharmaceutical combinations of oxycodone and naloxone
AB Disclosed in certain embodiments is a pharmaceutical composition comprising from 10 to 40 mg of oxycodone or a pharmaceutically acceptable salt thereof and 0.65 to 0.90 mg naloxone or a pharmaceutically acceptable salt thereof.

L8 ANSWER 21 OF 21 USPATFULL on STN
TI Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
AB A pharmaceutical composition for treating or preventing a disease, condition or symptoms thereof in a warm-blooded animal including a human, includes a therapeutically effective amount of an opioid agonist exhibiting potential pharmacologically addictive properties in warm blooded animals including humans; a side-effect reducing agent present in amounts sufficient to at least substantially neutralize the adverse side effects of the opioid agonist; an opioid antagonist present in a sequestered form in amounts sufficient to block the pharmacological effect of the opioid agonist upon release from the sequestered form; and

L8 ANSWER 4 OF 21 USPATFULL on STN
TI Sustained-release gel coated compositions
AB Disclosed in certain embodiments is a coating comprising a pharmaceutically acceptable mixture of gelatin and hydrophobic polymer.

ACCESSION NUMBER:	2003:270760 USPATFULL			
TITLE:	Sustained-release gel coated compositions			
INVENTOR(S):	Sackler, Richard S., Greenwich, CT, UNITED STATES Oshlack, Benjamin, New York, NY, UNITED STATES Wright, Curtis, Norwalk, CT, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003190362	A1	20031009	
APPLICATION INFO.:	US 2003-401111	A1	20030326	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2002-367832P		20020326	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 14th Floor, 485 Seventh Avenue, New York, NY, 10018			
NUMBER OF CLAIMS:	77			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1575			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PALM INTRANET

Day : Saturday
Date: 8/18/2007
Time: 15:29:26

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	**First Name**	
Oshlack	Benjamin	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Saturday
Date: 8/18/2007
Time: 21:33:36

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Wright	Curtis	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Saturday
Date: 8/18/2007
Time: 21:33:36

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Haddox	J. David	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Saturday
Date: 8/18/2007
Time: 21:33:36

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	**First Name**	
Haddox	J.	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

National Library of Medicine - Medical Subject Headings

2007 MeSH

MeSH Descriptor Data

Return to Entry Page

Standard View. Go to Concept View; Go to Expanded Concept View

MeSH Heading	Naltrexone
Tree Number	D03.132.577.249.706.550
Tree Number	D03.549.686.750.550
Tree Number	D03.605.497.750.550
Tree Number	D04.615.723.795.706.550
Scope Note	Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Entry Term	Antaxone
Entry Term	Bristol-Myers Squibb Brand of Naltrexone Hydrochloride
Entry Term	Celupan
Entry Term	Du Pont Brand of Naltrexone Hydrochloride
Entry Term	EN-1639A
Entry Term	Lacer Brand of Naltrexone Hydrochloride
Entry Term	Lamepro Brand of Naltrexone Hydrochloride
Entry Term	Nalorex
Entry Term	Naltrexone Hydrochloride
Entry Term	Nemexin
Entry Term	Orphan Brand of Naltrexone Hydrochloride
Entry Term	Pharmazam Brand of Naltrexone Hydrochloride
Entry Term	ReVia
Entry Term	Schering-Plough Brand of Naltrexone Hydrochloride
Entry Term	Trexan
Entry Term	United Drug Brand of Naltrexone Hydrochloride
Allowable Qualifiers	AA AD AE AG AI AN BL CF CH CL CS CT DU EC HI IM IP ME PD PK PO RE SD ST TO TU UR
Pharm. Action	Narcotic Antagonists

CAS Type 1 Name	Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-
Registry Number	16590-41-3
Previous Indexing	Cyclopropanes (1973-1975)
Previous Indexing	Morphinans (1973-1974)
Previous Indexing	Naloxone/analogs & derivatives (1975)
History Note	86(76); was see under NALOXONE 1976-85
Date of Entry	19750723
Unique ID	D009271

MeSH Tree Structures

Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Naloxone [D03.132.577.249.706]
▶ Naltrexone [D03.132.577.249.706.550]

Heterocyclic Compounds [D03]
Heterocyclic Compounds with 4 or More Rings [D03.549]
Morphinans [D03.549.686]
Naloxone [D03.549.686.750]
▶ Naltrexone [D03.549.686.750.550]

Heterocyclic Compounds [D03]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Naloxone [D03.605.497.750]
▶ Naltrexone [D03.605.497.750.550]

Polycyclic Compounds [D04]
Polycyclic Hydrocarbons, Aromatic [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Naloxone [D04.615.723.795.706]
▶ Naltrexone [D04.615.723.795.706.550]

Return to Entry Page **Link to NLM Cataloging Classification**

National Library of Medicine - Medical Subject Headings

2007 MeSH

MeSH Descriptor Data

Return to Entry Page

Standard View. Go to Concept View; Go to Expanded Concept View

MeSH Heading	Oxycodone
Tree Number	D03.132.577.249.547.547.149.575
Tree Number	D03.549.686.575.547.204.650
Tree Number	D03.605.497.575.547.204.650
Tree Number	D04.615.723.795.547.547.149.575
Annotation	do not confuse OXYCODONE x refs with HYDROCODONE x refs
Scope Note	Semisynthetic derivative of CODEINE that acts as a narcotic analgesic more potent and addicting than codeine.
Entry Term	Dihydrohydroxycodeinone
Entry Term	Dihydrone
Entry Term	Dinarkon
Entry Term	Eucodal
Entry Term	Hydroxycodeinon
Entry Term	Oxiconum
Entry Term	Oxycodeinon
Entry Term	Oxycodone Hydrochloride
Entry Term	Oxycone
Entry Term	Oxycontin
Entry Term	Pancodine
Entry Term	Percocet
Entry Term	Theocodin
Allowable Qualifiers	AA AD AE AG AI AN BL CF CH CL CS CT DU EC HI IM IP ME PD PK PO RE SD ST TO TU UR
Pharm. Action	Analgesics, Opioid
Pharm. Action	Antitussive Agents
Pharm. Action	Narcotics
CAS Type 1 Name	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-
Registry Number	76-42-6
Related Number	124-90-3 (HCl)
Previous Indexing	Ethers, Cyclic (1974-1975)
Previous	

Indexing	Morphinans (1969-1975)
History Note	91(76); was see under CODEINE 1976-90
Date of Entry	19750725
Unique ID	D010098

MeSH Tree Structures

Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Morphine [D03.132.577.249.547]
Morphine Derivatives [D03.132.577.249.547.547]
Codeine [D03.132.577.249.547.547.149]
Hydrocodone [D03.132.577.249.547.547.149.287]
▶ Oxycodone [D03.132.577.249.547.547.149.575]

Heterocyclic Compounds [D03]
Heterocyclic Compounds with 4 or More Rings [D03.549]
Morphinans [D03.549.686]
Morphine [D03.549.686.575]
Morphine Derivatives [D03.549.686.575.547]
Codeine [D03.549.686.575.547.204]
Hydrocodone [D03.549.686.575.547.204.540]
▶ Oxycodone [D03.549.686.575.547.204.650]

Heterocyclic Compounds [D03]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Morphine [D03.605.497.575]
Morphine Derivatives [D03.605.497.575.547]
Codeine [D03.605.497.575.547.204]
Hydrocodone [D03.605.497.575.547.204.540]
▶ Oxycodone [D03.605.497.575.547.204.650]

Polycyclic Compounds [D04]
Polycyclic Hydrocarbons, Aromatic [D04.615]

Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Morphine [D04.615.723.795.547]
Morphine Derivatives [D04.615.723.795.547.547]
Codeine [D04.615.723.795.547.547.149]
Hydrocodone [D04.615.723.795.547.547.149.287]
▶ Oxycodone [D04.615.723.795.547.547.149.575]

Return to Entry Page **Link to NLM Cataloging Classification**